GameChanger Advised Peptris Technologies On Licensing Agreement With Revio Therapeutics
GameChanger Advised Peptris Technologies On Licensing Agreement With Revio Therapeutics
GameChanger Law Advisors represented Peptris Technologies as they entered into a ground-breaking licensing agreement with Revio Therapeutics, through which Peptris has out-licensed its preclinical-stage asset 𝗣𝗘𝗣𝗥𝟭𝟮𝟰 (𝗥𝗧𝟬𝟬𝟭) for further development in Duchenne Muscular Dystrophy (DMD) – an extremely rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration, severe disability, and reduced life expectancy.